Are Variants Causing Cardiac Arrhythmia Risk Factors in Sudden Unexpected Death in Epilepsy?

Lauren E. Bleakley¹, Ming S. Soh¹, Richard D. Bagnall²,³, Lynette G. Sadleir⁴, Samuel Gooley⁵, Christopher Semsarian²,³, Ingrid E. Scheffer¹,⁵,⁶, Samuel F. Berkovic⁵ and Christopher A. Reid¹*

¹Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, Australia, ²Agnes Ginges Centre for Molecular Cardiology, Centenary Institute, The University of Sydney, Sydney, NSW, Australia, ³Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia, ⁴Department of Paediatrics and Child Health, University of Otago, Wellington, New Zealand, ⁵Department of Medicine, Epilepsy Research Centre, Austin Health, University of Melbourne, Heidelberg, VIC, Australia, ⁶Department of Paediatrics, Royal Children’s Hospital, University of Melbourne, Melbourne, VIC, Australia

Sudden unexpected death in epilepsy (SUDEP) is the most common cause of premature mortality in individuals with epilepsy. Acute and adaptive changes in heart rhythm in epilepsy implicate cardiac dysfunction as a potential pathogenic mechanism in SUDEP. Furthermore, variants in genes associated with Long QT syndrome (LQTS) have been identified in patients with SUDEP. LQTS is a cardiac arrhythmia condition that causes sudden cardiac death with strong similarities to SUDEP. Here, we discuss the possibility of an additive risk of death due to the functional consequences of a pathogenic variant in an LQTS gene interacting with seizure-mediated changes in cardiac function. Extending this general concept, we propose a hypothesis that common variants in LQTS genes, which cause a subtle impact on channel function and would not normally be considered risk factors for cardiac disease, may increase the risk of sudden death when combined with epilepsy. A greater understanding of the interaction between epilepsy, cardiac arrhythmia, and SUDEP will inform our understanding of SUDEP risk and subsequent potential prophylactic treatment.

Keywords: sudden unexpected death in epilepsy, epilepsy, cardiac arrhythmia, genetics, ion channels, common variants

INTRODUCTION

People with epilepsy have a two- to threefold increased risk of premature mortality, with sudden unexpected death in epilepsy (SUDEP) the most common epilepsy-related cause (1–5). SUDEP is defined as “a sudden, unexpected, witnessed or unwitnessed, non-traumatic and non-drowning death, occurring in benign circumstances, in an individual with epilepsy, with or without evidence for a seizure and excluding documented status epilepticus, in which postmortem examination does not reveal a cause of death.” (6). The incidence of SUDEP varies widely depending upon the subpopulation of interest, from 0.2 per 1,000 persons per year in children, and 1.2 per 1,000 persons per year in adults (7), to 2.46 or higher per 1,000 persons per year in people with refractory epilepsy (8, 9),...
and up to 10 per 1,000 persons per year in candidates for epilepsy surgery (10). In addition, certain severe epilepsy syndromes, such as the Developmental and Epileptic Encephalopathies (DEEs), place individuals at a greater risk of sudden death (11). A well-established example of this is Dravet syndrome, an intractable infantile-onset DEE mainly caused by pathogenic variants in SCN1A (12, 13). Dravet syndrome has a mortality rate of 16 per 1,000 persons per year, which translates to a 17% mortality risk in the first two decades of life with 59% of these deaths due to SUDEP (14). As expected, many rare variants in other genes that are closely associated with DEE have been identified in studies exploring the genetic architecture of SUDEP (11, 15).

Risk factors have been identified for SUDEP, with the most important being that the individual experiences tonic–clonic seizures, especially if they occur with high frequency (11, 16, 17). Other risk factors include epilepsy duration, age of onset of epilepsy, frequent changes in antiseizure medication doses, and, in some studies, antiepileptic drug polytherapy (3, 11, 16, 18). However, SUDEP can also occur in individuals with mild types of epilepsy (19, 20), as well as those with well-controlled epilepsy (3, 20), suggesting that other risk factors exist.

The pathophysiological mechanism(s) responsible for SUDEP remain largely unclear, despite considerable interest and research endeavor. A prevailing hypothesis is that SUDEP occurs following centrally mediated autonomic failure, which is most likely triggered by a tonic–clonic seizure (21). This hypothesis is strongly supported by a seminal paper, which reported findings from a systematic retrospective survey of SUDEP deaths that occurred in epilepsy video-electroencephalogram (video-EEG) monitoring units. This study found that SUDEP followed a consistent pattern whereby individuals had a tonic–clonic seizure (most were focal to bilateral tonic–clonic, and some were generalized tonic–clonic), followed by a period of rapid breathing, and then cardiorespiratory dysfunction leading to terminal apnea and asystole (22). Of particular note is the finding that terminal apnea always preceded terminal asystole (22). However, while these results are compelling, they are unlikely to be telling the whole story. The patient population in this study was small and involved individuals who were undergoing long-term monitoring, implying refractory epilepsy—a selected subset of patients who we know are at greater risk of SUDEP. Such a subset does not provide a representative sample of all individuals with SUDEP, raising the possibility that other pathological mechanisms can also cause SUDEP. One such mechanism, which has been widely studied, is the presence of abnormal cardiac rhythms (4, 15).

There are several lines of evidence supporting a role for cardiac arrhythmia in SUDEP. First, there are clear similarities between SUDEP and sudden cardiac death: in both cases, death is unexpected, and no cause of death is identified after comprehensive postmortem (23). Second, both human and animal studies show that seizure-mediated changes in cardiac electrophysiology occur, including seizure-driven cortical autonomic dysfunction and altered cardiac ion channel expression (24). Finally, recent genetic studies have found variants in genes associated with cardiac arrhythmia syndromes in some individuals with SUDEP (15, 25–28). Here, we propose that there may be an interaction between seizure activity and increased risk of sudden death in epilepsy patients who harbor variants (including common variants) in arrhythmogenic genes (Figure 1).

### ARRHYTHMOGENIC GENES IN SUDEP

A number of studies have explored the genetic architecture of SUDEP (25, 26, 29, 30). These studies have identified variation in several genes known to cause cardiac arrhythmia syndromes—in particular, long QT syndrome (LQTS)—and sudden death. LQTS is a cardiac arrhythmia syndrome resulting from delayed myocardial repolarization that manifests as a prolonged QT interval on the electrocardiogram (ECG) (31). This increases the risk of “torsades de pointes,” a distinctive form of ventricular tachycardia (32, 33) that can trigger sudden cardiac death in otherwise healthy individuals with structurally normal hearts (31). About 75% of familial LQTS is accounted for by three major genes, KCNQ1, KCNH2, and SCN5A (31). Variants in these three genes (25–28), and in several other cardiac and LQTS genes (25, 34), have been identified in SUDEP cases (Table 1).

It is important to highlight that the presence alone of a rare variant in a case of SUDEP does not confirm its pathogenicity or contribution to SUDEP risk. Furthermore, in cases of sudden death, where seizures have been diagnosed, but where pathogenic variants in cardiac genes are present, other potential explanations—such as misdiagnosis of convulsive syncope due to a cardiac cause, a common occurrence in individuals with LQTS—must be ruled out. This does not always occur (35, 36). A recent systematic review has highlighted the issues in diagnosis of SUDEP and the challenges in inferring causation in cases with variants in cardiac genes (37). That being said, current genetic findings that associate variants in cardiac arrhythmia genes with SUDEP do allow for some discussion and hypothesis generation about pathogenic mechanisms.

### POTENTIAL IMPACT OF SEIZURES IN PATIENTS HARBORING PATHOGENIC VARIANTS IN ARRHYTHMOGENIC GENES

The LQTS pathogenic variants in KCNH2, p.Arg744*, and p.Gly924Ala, have each been identified in a SUDEP patient (25). It is intuitive to think that an individual with epilepsy who also harbors a pathogenic cardiac genetic variant will be at higher risk of sudden unexpected death. The finding of validated LQTS variants in SUDEP provides indirect evidence supporting this premise (Table 1). It is also well-recognized that numerous acute postictal arrhythmia patterns occur in epilepsy patients, presumably through significant changes in autonomic function (38). It is possible that these rhythm changes could interact with the physiological consequences of harboring arrhythmogenic variants to increase the risk of sudden death (Figure 1). Data

---

**Abbreviations:** DEE, developmental and epileptic encephalopathy; ECG, electrocardiogram; EEG, electroencephalogram; LQTS, long QT syndrome; SUDEP, sudden unexpected death in epilepsy.
Bleakley et al. Cardiac Arrhythmia Variants in SUDEP

FIGURE 1 | Proposed mechanism on how genetic variants associated with cardiac arrhythmia may increase risk of sudden unexpected death in epilepsy (SUDEP).

(A) Comparison of surface electrocardiogram (ECG) in various conditions. (1) A normal QT interval in a healthy individual without epilepsy or cardiac arrhythmia (blue). (2) A small shift in the QT interval might occur in a patient with epilepsy during a seizure (purple). (3) A “subclinical” individual carrying a functional variant in a cardiac arrhythmia gene, which only subtly shifts the QT interval (orange). (4) A combination of a “subclinical” variant and a seizure event results in a nonlinear increase in the QT interval, thus increasing the risk of sudden death (red).

(B) The increased risk of sudden death that is conferred by harboring a “subclinical” functional variant in a cardiac gene presents itself in the acute context of a seizure, which causes disruption of normal cardiac function. Such cardiac disruption is more likely with longer seizures, seizures with more intense autonomic discharges, and perhaps more violent seizures with more systemic metabolic changes, all effects encapsulated by the term “seizure severity.” This risk is present on every occasion when an affected individual has a seizure.

from the Kcnq1 p.Thr311Ile mouse model of LQTS provides more direct evidence that an interaction between acute seizures and elongation of the QT interval may occur. This mouse has a prolonged QT interval and frequent seizures relative to controls (39, 40), and interestingly, over half of ECG-detected cardiac abnormalities are associated with epileptiform discharges on the EEG (40). Furthermore, we know that in many epilepsy patient populations and animal models of epilepsy, basal ECG properties...
are changed (24). In patients who also harbor underlying variants in arrhythmogenic genes, these long-term changes in heart rhythm may increase the risk of sudden death. It will be challenging to rigorously test whether seizures increase the risk of sudden death in patients harboring pathogenic LQTS variants. Designs could include cross-sectional analyses of families with LQTS and determining if the death rate is higher in those with known coexistent epilepsy or longitudinal follow-up of subjects with epilepsy stratified into those with and without known LQTS variants.

**CAN “SUBCLINICAL” VARIANTS IN ARRHYTHMOCGENIC GENES CONTRIBUTE TO SUDEP RISK?**

Consider a potentially more broadly applicable situation, where a patient with epilepsy harbors a common variant in a gene associated with cardiac arrhythmia, but the variant is not normally associated with clinical events. Such a “subclinical” variant alters cardiac function but to a degree that is below the threshold to cause clinically recognized LQTS; thus, it would not normally be considered a risk factor for cardiac disease. Could patients such as this be at an increased risk of death during or immediately following seizures (Figure 1)? We propose that small shifts in the QT interval, which are present in seizures and independently in people harboring common variants in arrhythmogenic genes that cause minor changes in channel function, will only increase the risk of sudden death slightly. However, when combined, seizures and a common variant in an arrhythmogenic gene may interact to significantly increase SUDEP risk.

There is a precedent for this idea in a recently published study that investigated the relationship between KCNQ1 common variants and sudden death during illegal drug use. The missense variant KCNQ1 p.Gly643Ser (found 1,433 times in the gnomAD database) was more common in patients who died of drug-related causes than in the general population (41). Interestingly, this common variant has been found to cause a mild loss-of-function of the Kv7.1 voltage-gated potassium channel when studied in a heterologous expression assay (42, 43). This finding

---

**TABLE 1 | Nonsynonymous variants in cardiac arrhythmia genes that have been identified in sudden unexpected death in epilepsy (SUDEP).**

| Gene  | Variant       | gnomAD allele count | Sorting intolerant from tolerant (SIFT)           | PolyPhen-2       | References |
|-------|---------------|---------------------|-------------------------------------------------|------------------|------------|
| AKAP9 | Ile1749Thr    | 195                 | Deleterious                                     | Probably damaging| (25)       |
|       | Arg2607Gly    | 0                   | Deleterious                                     | Probably damaging| (25)       |
| ANK2  | Ala1027Asp    | 0                   | Deleterious                                     | Probably damaging| (25)       |
|       | Ser2440Asn    | 0                   | Deleterious                                     | Probably damaging| (25)       |
|       | Ile3903Asn    | 1                   | Deleterious                                     | Probably damaging| (25)       |
| HCN1  | Gly46Val      | 0                   | Deleterious                                     | Benign           | (34)       |
| HCN2  | Phe738Cys     | 0                   | Tolerated                                       | Probably damaging| (34)       |
|       | Pro802Ser     | 10                  | Tolerated low confidence                        | Benign           | (34)       |
| HCN3  | Lys69Arg      | 3,014               | Tolerated                                       | Benign           | (34)       |
|       | Pro630Leu     | 6,780               | Deleterious low confidence                      | Benign           | (34)       |
| HCN4  | Gly363Glu     | 7,166               | Deleterious low confidence                      | Benign           | (34)       |
|       | Val759Ile     | 870                 | Tolerated                                       | Benign           | (34)       |
|       | Gly973Arg     | 19                  | Tolerated low confidence                        | Possibly damaging| (34)       |
|       | Arg1044Trp    | 4                   | Deleterious low confidence                      | Possibly damaging| (34)       |
|       | Glu1193Gln    | 205                 | Tolerated low confidence                        | Probably damaging| (25)       |
| KCNH2 | Ile82Thr      | 0                   | Deleterious                                     | Benign           | (28)       |
|       | Arg176Trp     | 44                  | Deleterious                                     | Possibly damaging| (28)       |
|       | Arg744*       | 0                   | Deleterious                                     | Possibly damaging| (25)       |
|       | Gly749Ala     | 0                   | Deleterious                                     | Possibly damaging| (25)       |
|       | Gly924Ala     | 8                   | Tolerated                                       | Possibly damaging| (25)       |
|       | Arg1047Leu    | 3,117               | Tolerated                                       | Possibly damaging| (28)       |
| KCNQ1 | Tyr662*       | 12                  | Tolerated                                       | Benign           | (25)       |
| RYR2  | Cys1489Arg    | 40                  | Tolerated                                       | Benign           | (25)       |
| SCN5A | Val2233Gly    | 0                   | Deleterious                                     | Probably damaging| (25)       |
|       | Ile397Val     | 1                   | Deleterious                                     | Probably damaging| (25)       |
|       | Arg523Cys     | 2                   | Deleterious                                     | Benign           | (27)       |
|       | His558Arg     | 62,556              | Tolerated                                       | Benign           | (28)       |
|       | Ala572Asp     | 1,451               | Tolerated                                       | Benign           | (28)       |
|       | Pro1090Leu    | 458                 | Tolerated                                       | Benign           | (28)       |
|       | Pro2006Ala    | 252                 | Tolerated low confidence                        | Benign           | (28)       |

*indicates a nonsense mutation resulting in a premature stop codon.
provides evidence that a common variant, which is unlikely to be pathogenic in isolation, could potentially increase the risk of death under certain circumstances.

Numerous common variants in LQTS genes have been identified in SUDEP patients (25–28) (Table 1). This is exemplified by variation in KCNH2, a cardiac gene that encodes the α subunit of the voltage-gated potassium channel K_{v}11.1 (44). The common KCNH2 p.Arg1047Leu variant (found >3,000 times in gnomAD) has been observed in four patients that have suffered SUDEP (26). Functional testing of this variant suggests that it causes mild loss of channel function (45). It is well-established that loss-of-function KCNH2 variants cause LQTS type 2, which does predispose individuals to greater risk of sudden death (31, 44, 46, 47). As such, although the KCNH2 p.Arg1047Leu variant is not disease causing in its own right, the mild loss-of-function that it causes positions it as a potential risk factor for SUDEP. Owing to the prevalence of this variant in the population, very large sample sizes would be needed to show a statistical association with SUDEP, with a similar issue arising with all common variants in LQTS genes that are identified in patients.

**CONCLUSION AND POTENTIAL CLINICAL IMPLICATIONS**

For patients with epilepsy and their families, SUDEP is a frightening possibility, made even more so by its unpredictability. SUDEP is undoubtedly a highly heterogeneous condition, and a given individual’s risk is likely to be determined by a complex interaction of many contributing factors. These include both genetic and environmental risk factors for mechanisms as diverse as seizures, cardiac arrhythmias, respiratory dysfunction, and autonomic dysfunction (15). Reducing seizure frequency and severity is important in reducing SUDEP risk. However, in such a multifactorial condition, the potential risk conferred by other mechanisms—such as cardiac arrhythmias—also warrants consideration. Variants in diverse cardiac arrhythmia genes have been found in SUDEP patients (25–29, 34), but we clearly need a much better understanding of the impact of these variants in the context of an individual with epilepsy.

Although it seems obvious, an increased risk of death associated with an epilepsy patient having a validated LQTS variant has not been shown. It is also not known whether SUDEP risk increases in cases of epilepsy when a patient harbors one or more variants of unknown significance in cardiac arrhythmia genes, such as in the case of the patients with the KCNH2 p.Arg1047Leu common variant outlined above. We propose that genetic studies in SUDEP should be extended to include the characterization of common variants in cardiac arrhythmia genes. Additionally, functional studies are required to identify if these variants cause subclinical biophysical changes, which could exacerbate the risk of sudden death during a seizure.

Currently, the prevalence of rare variants with functional impact is unknown. Without such information, and indeed until such time as the genetic architecture of SUDEP overall is understood, we are unable to predict the relative contribution of genetic cardiac dysfunction to SUDEP incidence and risk.

Identifying and confirming genetic risk factors that predispose patients with epilepsy to cardiac arrhythmia would have therapeutic implications. Patients identified to be at risk of cardiac arrhythmia could be advised to avoid medications that interact with cardiac ion channels; commence prophylactic treatment with beta blockers, which are used effectively in LQTS to reduce the risk of life-threatening arrhythmias (48); or even consider the implantation of an internal defibrillator or pacemaker to reduce risk of sudden death (49), although evidence for the benefit of such an approach is currently limited (50). Concurrent EEG and ECG monitoring may also be warranted to gain greater insight into the interactions between seizures and cardiac rhythm.

In summary, here we highlight that variants in cardiac genes, both those known to be pathogenic and also those that are currently thought of as “subclinical,” are potential contributors to SUDEP risk. However, there is currently a lack of direct evidence for cardiac variants increasing the risk of SUDEP, demonstrating a need for further research. Given the sample-size challenges of clinical research in this area, we suggest that exploring this hypothesis in experimental animals is a useful next step.

**DATA AVAILABILITY STATEMENT**

All datasets generated for this study are included in the article/supplementary material.

**AUTHOR CONTRIBUTIONS**

LB, MS, RB, LS, CS, IS, SB, and CR developed the concept. LB and CR wrote the manuscript. MS generated the figure. All authors contributed to revising and editing the manuscript and approved the submitted version.

**FUNDING**

This work was supported by the National Health and Medical Research Council (NHMRC) Program Grant (10915693) to SB, IS, and CR; by Cure Kids New Zealand to LS; and by an anonymous philanthropic gift for SUDEP research to SB and IS. CR would like to acknowledge the CURE foundation for support. CS was the recipient of an NHMRC Practitioner Fellowship (#1154992). IS holds an NHMRC Practitioner Fellowship and an Investigator Fellowship. LB acknowledges the support of an Australian Government Research Training Program Scholarship. The Florey Institute of Neuroscience and Mental Health were supported by the Victorian State Government infrastructure funds.

**ACKNOWLEDGMENTS**

We thank Marie Phillips for carefully reading and providing feedback on this manuscript.
REFERENCES

1. Sander JW, Bell GS. Reducing mortality: an important aim of epilepsy management. J Neurol Neurosurg Psychiatry. (2004) 75:419–51. doi: 10.1136/jnnp.2003.029223

2. Bell GS, Sander JW. The epidemiology of epilepsy: the size of the problem. Seizure. (2001) 10:306–14; quiz 15–6. doi: 10.1053/seiz.2001.0584

3. Hitiris N, Suratman S, Kelly K, Stephen LJ, Sills GJ, Brodie MJ. Sudden unexpected death in epilepsy: a search for risk factors. Epilepsy Behav. (2007) 10:138–41. doi: 10.1016/j.yebeh.2006.11.010

4. Tomson T, Nashef L, Ryvlin P. Sudden unexpected death in epilepsy: current knowledge and future directions. Lancet Neurol. (2008) 7:1021–31. doi: 10.1016/S1474-4422(08)70202-3

5. Thurman DJ, Logrosino G, Beghi E, Hauser WA, Hesdorffer DC, Newton CR, et al. The burden of premature mortality of epilepsy in high-income countries: a systematic review from the Mortality Task Force of the International League Against Epilepsy. Epilepsia. (2017) 58:17–26. doi: 10.1111/epi.13604

6. Nashef L, So EL, Ryvlin P, Tomson T. Unifying the definitions of sudden unexpected death in epilepsy. Epilepsia. (2012) 53:227–33. doi: 10.1111/j.1528-1167.2011.03358.x

7. Hardy C, Tomson T, Gloss D, Buchhalter J, Cross H, Donner E, et al. Practice guideline summary: sudden unexpected death in epilepsy incidence rates and risk factors: report of the guideline development, dissemination, and implementation subcommittee of the american academy of neurology and the american epilepsy society. Neurology. (2017) 88:1674–80. doi: 10.1212/WNL.0000000000003685

8. DeGiorgio CM. Editorial: sudden death in epilepsy: basic and translational research. Front Neurol. (2018) 9:484. doi: 10.3389/fneur.2018.00484

9. Mohanraj R, Norrie J, Stephen LJ, Kelly K, Hitiris N, Brodie MJ. Mortality in adults with newly diagnosed and chronic epilepsy: a retrospective comparative study. Lancet Neurol. (2006) 5:481–7. doi: 10.1016/S1474-4422(06)70448-3

10. Téllez-Zenteno JF, Ronquillo LH, Wiebe S. Sudden unexpected death in epilepsy: evidence-based analysis of incidence and risk factors. Epilepsy Res. (2005) 65:101–15. doi: 10.1016/j.eplepsie.2005.05.004

11. Devinsky O, Hesdorffer DC, Thurman DJ, Lhatoo S, Richerson G. Sudden unexpected death in epilepsy: epidemiology, mechanisms, and prevention. Lancet Neurol. (2016) 15:1075–88. doi: 10.1016/S1474-4422(16)30158-2

12. De Jonghe P. Molecular genetics of Dravet syndrome. Dev Med Child Neurol. (2011) 53 (Suppl. 2):7–10. doi: 10.1111/j.1540-8665.2011.03965.x

13. Richards KL, Milligan CJ, Richardson RJ, Jancovska N, Grunnet M, Jacobson LH, et al. Selective NaV1.1 activation rescues Dravet syndrome mice from seizures and premature death. Proc Natl Acad Sci USA. (2018) 115:E8077–885. doi: 10.1073/pnas.1800476115

14. Cooper MS, McIntosh A, Crompton DE, McMahon JM, Schneider A, et al. Practice guideline summary: sudden unexpected death in epilepsy cases. Brain Pathol. (2011) 21:692–8. doi: 10.1111/j.1528-1167.2011.00500.x

15. Hunt DPJ, Tang K. Long QT syndrome presenting as epileptic seizures in an adult. Emerg Med J. (2005) 22:600–1. doi: 10.1136/emj.2003.007997

16. MacCormick JM, McAlister H, Crawford J, French JK, Crozier JL, Shellng AN, et al. Misdiagnosis of long QT syndrome as epilepsy at first presentation. Ann Emerg Med. (2009) 54:26–32. doi: 10.1016/j.annemergmed.2009.01.031

17. Schwartz PJ, Crotti L, Insolia R. Long QT syndrome from genetics to management. Circ Arrhythm Electrophysiol. (2012) 5:868–77. doi: 10.1161/CIRCEP.111.962019

18. Tu E, Waterhouse L, Duflo J, Bagnall RD, Semasarian C. Genetic analysis of hyperpolarization-activated cyclic nucleotide-gated cation channels in sudden unexpected death in epilepsy cases. Brain Pathol. (2011) 21:692–8. doi: 10.1111/j.1528-1167.2011.00500.x

19. van der Lende M, Surges R, Sander JW, Thijs RD. Cardiac arrhythmias during or after epileptic seizures. J Neurol Neurosurg Psychiatry. (2016) 87:69–74. doi: 10.1136/jnnp.2015.078966

20. Banai S, Tzivoni D. Drug therapy for torsade de pointes. J Cardiovasc J. (2006) 84:555–64. doi: 10.1016/j.cardio.2004.06.1043

21. MacCormick JM, McAlister H, Crawford J, French JK, Crozier JL, Shellng AN, et al. Misdiagnosis of long QT syndrome as epilepsy at first presentation. Ann Emerg Med. (2009) 54:26–32. doi: 10.1016/j.annemergmed.2009.01.031

22. Ryvlin P, Nashef L, Lhatoo SD, Bateman LM, Bird J, Bleasel A, et al. Incidence and mechanisms of cardiorespiratory arrests in epilepsy monitoring units (MORTEMUS): a retrospective study. Lancet Neurol. (2013) 12:966–77. doi: 10.1016/S1474-4422(13)70214-X

23. Bagnall RD, Weintraub RG, Ingles J, Duflo J, Yeates L, Lam L, et al. A prospective study of sudden cardiac death among children and young adults. N Engl J Med. (2016) 374:2441–52. doi: 10.1056/NEJMoa1510687

24. Casimiro MC, Knollmann BC, Yamaoh EN, Nie L, Vary JC, Sirenko SG, et al. Targeted point mutagenesis of mouse KCNQ1: phenotypic analysis of mice with point mutations that cause Romano-Ward syndrome in humans. Genomics. (2004) 84:555–64. doi: 10.1016/j.ygeno.2004.06.007

25. Nagasawa S, Saltz H, Kasahara S, Chiba F, Torimitsu S, Abe H, et al. Relationship between KCNQ1 (LQT1) and KCNH2 (LQT2) gene mutations and sudden death during illegal drug use. Sci Rep. (2018) 8:8443. doi: 10.1038/s41598-018-26723-8

26. Kubota T, Horie M, Takano M, Yoshida K, Takenaka K, Watanabe E, et al. Evidence for a single nucleotide polymorphism in
the KCNQ1 potassium channel that underlies susceptibility to life-threatening arrhythmias. J Cardiovasc Electrophysiol. (2001) 12:1223–9. doi: 10.1046/j.1540-8167.2001.01223.x

43. Villa C, Combi R. Potassium channels and human epileptic phenotypes: an updated overview. Front Cell Neurosci. (2016) 10:81. doi: 10.3389/fncel.2016.00081

44. Smith JL, Anderson CL, Burgess DE, Elayi CS, January CT, Delisle BP. Molecular pathogenesis of long QT syndrome type 2. J Arrhythm. (2016) 32:373–80. doi: 10.1016/j.joa.2015.11.009

45. Chevalier P, Bellocq C, Millat G, Piqueras E, Potet F, Schott JJ, et al. Torsades de pointes complicating atrioventricular block: evidence for a genetic predisposition. Heart Rhythm. (2007) 4:170–4. doi: 10.1016/j.hrthm.2006.10.004

46. Liu L, Tian J, Lu C, Chen X, Fu Y, Xu B, et al. Electrophysiological characteristics of the LQT2 syndrome mutation KCNH2-G572S and regulation by accessory protein KCNE2. Front Physiol. (2016) 7:650. doi: 10.3389/fphys.2016.00650

47. Murphy C, Gill J. Long-QT syndrome in a family with a KCNH2 mutation. Heart Metab. (2008) 41:30–3.

48. Ackerman MJ, Priori SG, Dubin AM, Kowey P, Linker NJ, Slotwiner D, et al. Beta-blocker therapy for long QT syndrome and catecholaminergic polymorphic ventricular tachycardia: are all beta-blockers equivalent? Heart Rhythm. (2017) 14:e11–e4. doi: 10.1016/j.hrthm.2016.09.012

49. Rugg-Gunn FI, Simister RJ, Squirell M, Holdright DR, Duncan JS. Cardiac arrhythmias in focal epilepsy: a prospective long-term study. Lancet. (2004) 364:2212–9. doi: 10.1016/S0140-6736(04)17594-6

50. Dlouhy BJ, Gehlbach BK, Richerson GB. Sudden unexpected death in epilepsy: basic mechanisms and clinical implications for prevention. J Neurol Neurosurg Psychiatry. (2016) 87:402–13. doi: 10.1136/jnnp-2013-307442

Conflict of Interest: LS was a consultant for the Epilepsy Consortium, has received research funding from Zynexa, and has received research funding from Zynexa, the Health Research Council of New Zealand and Cure Kids New Zealand. IS has served on scientific advisory boards for UCB, Eisai, GlaxoSmithKline, BioMarin, Nutricia, Rogcon, and Xenon Pharmaceuticals; has received speaker honoraria from GlaxoSmithKline, UCB, BioMarin, Biocodex and Eisai; has received funding for travel from UCB, Biocodex, GlaxoSmithKline, BioMarin and Eisai; has served as an investigator for Zogenix, Zynexa, Ultragenyx, GW Pharma, UCB, Eisai, Anavex Life Sciences, Ovid Therapeutics, Epigenex, Encoded Therapeutics and Marinus; and has consulted for Zynexa Pharmaceuticals, Atheneum Partners, Ovid Therapeutics, Epilepsy Consortium and UCB. SB declares unrestricted educational grants from UCB Pharma, SciGen and Eisai and consultancy fees from Praxis Precision Medicines.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Bleakley, Soh, Bagnall, Sadleir, Gooley, Semsarian, Scheffer, Berkovic and Reid. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Author/s: Bleakley, LE; Soh, MS; Bagnall, RD; Sadleir, LG; Gooley, S; Semsarian, C; Scheffer, IE; Berkovic, SF; Reid, CA

Title: Are Variants Causing Cardiac Arrhythmia Risk Factors in Sudden Unexpected Death in Epilepsy?

Date: 2020-09-08

Citation: Bleakley, L. E., Soh, M. S., Bagnall, R. D., Sadleir, L. G., Gooley, S., Semsarian, C., Scheffer, I. E., Berkovic, S. F. & Reid, C. A. (2020). Are Variants Causing Cardiac Arrhythmia Risk Factors in Sudden Unexpected Death in Epilepsy?. FRONTIERS IN NEUROLOGY, 11, https://doi.org/10.3389/fneur.2020.00925.

Persistent Link: http://hdl.handle.net/11343/252592

File Description: Published version

License: CC BY